Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05544604
Other study ID # 453
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date May 1, 2020
Est. completion date December 14, 2022

Study information

Verified date December 2022
Source South Egypt Cancer Institute
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study is designed to evaluate the effect of two concentric electrode transcranial direct current stimulation over the primary motor cortex versus insular cortical targets in post mastectomy neuropathic pain.


Description:

eighty patients within age group 18-65 years old with post mastectomy neuropathic pain that are resistant to medical treatment in the form of tramadol hydrochloride 100 mg twice daily, pregabalin 75 mg twice daily and Amitriptyline 25 mg once daily for at least two months or associated with significant adverse effect from medication will be involved in this study. twenty patients will be randomly allocated into one of the study designed groups using serially numbered opaque closed envelopes. Each patient will be placed in the appropriate group after opening the corresponding sealed envelope. The patient will receive one of the following interventions either: - active tDCS (2 mA) targeting the primary motor cortex of the contralateral side of the pain for 20 minute duration for five sessions in five consecutive days (one session /day), - sham tDCS over the primary motor cortex in the same stimulation parameters will be used but the device will be turned off without patient knowledge after 30 seconds , - active tDCS (2mA) targeting the insula of the contralateral side of the pain for 20 minute duration for five sessions in five consecutive days (one session /day), - sham tDCS over the insula in the same stimulation parameters will be used but the device will be turned off without patient knowledge after 30 seconds.


Recruitment information / eligibility

Status Completed
Enrollment 80
Est. completion date December 14, 2022
Est. primary completion date December 30, 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria: - eighty patients within age group 18-65 years old with post mastectomy neuropathic pain that are resistant to medical treatment in the form of tramadol hydrochloride 100 mg twice daily, pregabalin 75 mg twice daily and Amitriptyline 25 mg once daily for at least two months or associated with significant adverse effect from medication will be involved in this study. Exclusion Criteria: - We will exclude patients with intracranial metallic devices or with pacemakers or any other device. We also exclude those with extensive myocardial ischemia and those known to have epilepsy

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Transcranial direct current stimulation
tDCS will be delivered with current strength of 2 mA for 20 min . Current will be applied through two concentric electrodes target electrode; return electrode. First we will fill the electrode cage with an electroconductive gel, and then position the electrodes, with the target electrode over the FDI hotspot, and finally we fasten the electrodes with a tubular net-shaped elastic bandage in mesh tissue, making sure that it will not push the electrode forward or backward. This procedure will aim at reducing contact impedance and at creating a uniform adherence between the whole surface of the electrodes and the scalp, avoiding uneven distribution of the current (Fertonani, 2015). We will position the central electrode (anode) according to the study group over C3 or C4 , the stimulating electrode will be placed on the scalp at T7 or T8 for the insular cortex per the 10-20 (EEG) system.

Locations

Country Name City State
Egypt South Egypt Cancer Institute Assiut

Sponsors (2)

Lead Sponsor Collaborator
South Egypt Cancer Institute Assiut University

Country where clinical trial is conducted

Egypt, 

Outcome

Type Measure Description Time frame Safety issue
Primary chronic postmastectomy pain relief pain relief on the VAS after the 5th session VAS monitoring after 5th session
Primary chronic postmastectomy pain relief pain relief on the VAS after 15 days VAS monitoring after 15 days
Primary chronic postmastectomy pain relief pain relief on the VAS 1 month later VAS monitoring one month later
Secondary VDS, LANSS and depression symptoms by HAM-D VDS, LANSS and depression symptoms by HAM-D after the 5th session VDS, LANSS and depression symptoms by HAM-D after 5th session
Secondary VDS, LANSS and depression symptoms by HAM-D VDS, LANSS and depression symptoms by HAM-D after 15 days VDS, LANSS and depression symptoms by HAM-D after 15 days
Secondary VDS, LANSS and depression symptoms by HAM-D VDS, LANSS and depression symptoms by HAM-D 1 month later VDS, LANSS and depression symptoms by HAM-D after one month
See also
  Status Clinical Trial Phase
Terminated NCT03656679 - Paravertebral Versus Pectoralis Block for Post Mastectomy Pain N/A
Completed NCT04530526 - Surgical Treatment of Post-surgical Mastectomy Pain Utilizing the Regenerative Peripheral Nerve Interface N/A
Active, not recruiting NCT03090776 - Prevention of Post Mastectomy With Intraoperative Ketamine Early Phase 1
Completed NCT03374423 - Radiofrequency for Chronic Post-mastectomy Pain: is it Better to Target Intercostal Nerves or Corresponding Dorsal Root Ganglia? N/A
Recruiting NCT05494281 - Serratus Anterior Plane Block to Prevent Chronic Postoperative Pain in Breast Cancer N/A
Completed NCT03494426 - Radiofrequency Thoracic Sympathectomy for Chronic Postmastectomy Pain; Randomized Placebo Controlled Study N/A